Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06471946
Recruiting Phase 1/2

VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS

NCT06471946 · tracked via the Priya Life Science China tracker
Sponsor
Navy General Hospital, Beijing
Phase
Phase 1/2
Started
2024-10-01
Last updated
2024-10-01

Condition(s) studied

Higher-risk Myelodysplastic Syndromes

Investigational drug(s) / intervention(s)

Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT →

Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT: Patients were treated by VA Conditioning Regimen Allo-HSCT: Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg/m2 subcutaneous injection qd d1-7, donor stem cells infused from d9

Study summary

The goal of this phase 1/2 trial is to test the safety and efficacy of Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT in treating patients with higher-risk MDS.

Eligibility

Sex
ALL
Min age
70 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * The patient should, in the investigator's opinion, be able to meet all clinical trial requirements. * The patient is willing and able to adhere to the study visit schedule and other protocol requirements. * The patient should be diagnosed with higher risk MDS according to the standard criteria of the World Health Organization (WHO). Exclusion Criteria: * Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment. * Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.

Primary outcome measure(s)

  • Overall Survival — 3 year
    OS was defined as time from diagnosis to death from any cause or the last follow-up

Trial sites (1)

FacilityCityRegionStatus
Navy General Hospital Beijing Beijing Municipality Recruiting

More Navy General Hospital, Beijing trials in China

Smart Technology Facilitated Patient-centered Venous Thromboembolism Management Starting soon
Smart Technology Facilitated Patient-centered Venous Thromboembolism Management Enrolling by invitation
Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy Recruiting
Effect of Aerobic Interval Training on Atrial Fibrillation Burden Starting soon
Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas Recruiting

Other trials for the same condition

A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06471946 on ClinicalTrials.gov ↗ ← All trials in China